{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:42:56Z","timestamp":1767969776224,"version":"3.49.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.ejca.2010.04.004","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T08:50:49Z","timestamp":1273135849000},"page":"1967-1978","source":"Crossref","is-referenced-by-count":178,"title":["Nasopharyngeal carcinoma: The next challenges"],"prefix":"10.1016","volume":"46","author":[{"given":"Albiruni R.A.","family":"Razak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.04.004_bib1","first-page":"125","article-title":"Nasopharyngeal carcinoma: an epidemiological approach to carcinogenesis","volume":"33","author":"Jeannel","year":"1999","journal-title":"Cancer Surv"},{"key":"10.1016\/j.ejca.2010.04.004_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2010.04.004_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0215(20000201)85:3<358::AID-IJC11>3.0.CO;2-E","article-title":"Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China","volume":"85","author":"Yuan","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<675::AID-IJC2>3.0.CO;2-J","article-title":"Diet and nasopharyngeal cancer in a low-risk population","volume":"78","author":"Farrow","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib5","first-page":"376","article-title":"Nasopharyngeal carcinoma: the Epstein-Barr virus association","volume":"21","author":"Liebowitz","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1044579X02000883","article-title":"Genetic and epigenetic changes in nasopharyngeal carcinoma","volume":"12","author":"Lo","year":"2002","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejca.2010.04.004_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.2910170102","article-title":"Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma","volume":"17","author":"Henle","year":"1976","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199509143331103","article-title":"Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma","volume":"333","author":"Pathmanathan","year":"1995","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib9","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa011610","article-title":"Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men","volume":"345","author":"Chien","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/2281056a0","article-title":"EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx","volume":"228","author":"zur Hausen","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2010.04.004_bib11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/1097-0142(19830715)52:2<362::AID-CNCR2820520230>3.0.CO;2-V","article-title":"Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy","volume":"52","author":"Hsu","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(97)07269-3","article-title":"Nasopharyngeal carcinoma","volume":"350","author":"Vokes","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.04.004_bib13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib14","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","article-title":"Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety","volume":"23","author":"Wee","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/cncr.20358","article-title":"Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group","volume":"101","author":"Hui","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ijrobp.2004.07.702","article-title":"Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience","volume":"61","author":"Lee","year":"2005","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0360-3016(02)02724-4","article-title":"Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience","volume":"53","author":"Lee","year":"2002","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib18","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1200\/JCO.2006.07.7982","article-title":"Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma","volume":"24","author":"Leung","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib19","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib20","first-page":"6878","article-title":"Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA","volume":"60","author":"Lo","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib21","first-page":"113","article-title":"Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC)","volume":"16","author":"Liu","year":"1998","journal-title":"Radiat Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2006.07.012","article-title":"Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma","volume":"67","author":"Twu","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib23","unstructured":"A trial of adjuvant chemotherapy in nasopharyngeal carcinoma patients with residual Epstein-Barr virus (EBV) DNA following radiotherapy. <http:\/\/www.clinicaltrials.gov> [Accessed 11.03.10]."},{"key":"10.1016\/j.ejca.2010.04.004_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/14737159.7.3.261","article-title":"Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response","volume":"7","author":"Felip","year":"2007","journal-title":"Exp Rev Mol Diagn"},{"key":"10.1016\/j.ejca.2010.04.004_bib25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib26","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2006.09.7915","article-title":"Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer","volume":"25","author":"Cobo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib27","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-04-2216","article-title":"ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin\/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer","volume":"11","author":"Viguier","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib28","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/annonc\/mdp065","article-title":"Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma \u2013 correlation with excision repair cross-complementing-1 polymorphisms","volume":"20","author":"Ma","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdi127","article-title":"Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20\u201321 March 2004, under the auspices of ESMO","volume":"16","author":"Blay","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2008.01.009","article-title":"Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas","volume":"87","author":"Lee","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib31","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.ijrobp.2006.02.031","article-title":"18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma","volume":"65","author":"Yen","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.radonc.2007.11.002","article-title":"FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review","volume":"85","author":"Liu","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1586\/14737140.8.3.311","article-title":"Authentication of cell lines: ignore at your peril!","volume":"8","author":"Freshney","year":"2008","journal-title":"Exp Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2010.04.004_bib34","first-page":"167","article-title":"Genetic markers as tracers in cell culture","volume":"26","author":"Gartler","year":"1967","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejca.2010.04.004_bib35","first-page":"1095","article-title":"Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA","volume":"29","author":"Takaoka","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib36","doi-asserted-by":"crossref","first-page":"e6040","DOI":"10.1371\/journal.pone.0006040","article-title":"Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2","volume":"4","author":"Phuchareon","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2010.04.004_bib37","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/ijc.23374","article-title":"Authentication of nasopharyngeal carcinoma tumor lines","volume":"122","author":"Chan","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib38","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1073\/pnas.121616198","article-title":"Short tandem repeat profiling provides an international reference standard for human cell lines","volume":"98","author":"Masters","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ejca.2010.04.004_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F","article-title":"Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus","volume":"83","author":"Cheung","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib40","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1016\/j.juro.2009.01.108","article-title":"The use of short tandem repeat profiling to characterize human bladder cancer cell lines","volume":"181","author":"Chiong","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2010.04.004_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1749-0774.2005.00007.x","article-title":"Essential role for gene profiling analysis in the authentication of human cell lines","volume":"19","author":"Yoshino","year":"2006","journal-title":"Human Cell"},{"key":"10.1016\/j.ejca.2010.04.004_bib42","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1158\/1078-0432.CCR-09-1364","article-title":"What\u2019s your line?","volume":"15","author":"Potash","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1535-6108(04)00119-9","article-title":"Focus on nasopharyngeal carcinoma","volume":"5","author":"Lo","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2010.04.004_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00005537-200401000-00029","article-title":"Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx","volume":"114","author":"Leong","year":"2004","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejca.2010.04.004_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0385-8146(01)00135-3","article-title":"Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma","volume":"29","author":"Fujii","year":"2002","journal-title":"Auris, Nasus, Larynx"},{"key":"10.1016\/j.ejca.2010.04.004_bib46","first-page":"1197","article-title":"Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma","volume":"21","author":"Segawa","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2010.04.004_bib47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.virusres.2005.07.010","article-title":"Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status","volume":"115","author":"Krishna","year":"2006","journal-title":"Virus Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-6-1","article-title":"Elevated expressions of survivin, VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma","volume":"6","author":"Li","year":"2008","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0165-4608(01)00542-8","article-title":"Absence of evidence for HER2 amplification in nasopharyngeal carcinoma","volume":"132","author":"Yan","year":"2002","journal-title":"Cancer Gen Cytogen"},{"key":"10.1016\/j.ejca.2010.04.004_bib50","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hed.10307","article-title":"Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma \u2013 a prospective study","volume":"25","author":"Ma","year":"2003","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2010.04.004_bib51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12032-008-9124-5","article-title":"PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival","volume":"26","author":"Chou","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib52","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ijc.21444","article-title":"PIK3CA mutations in nasopharyngeal carcinoma","volume":"118","author":"Or","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib53","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1111\/j.1349-7006.2009.01292.x","article-title":"PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma","volume":"100","author":"Fendri","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2010.04.004_bib54","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.1158\/0008-5472.CAN-05-0648","article-title":"Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma","volume":"65","author":"Hui","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib55","first-page":"589","article-title":"Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma","volume":"62","author":"Qian","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib56","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/01.MP.0000089778.48167.91","article-title":"Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach","volume":"16","author":"Bar-Sela","year":"2003","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2010.04.004_bib57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.oraloncology.2006.04.004","article-title":"Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma \u2013 a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor","volume":"43","author":"Chan","year":"2007","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib58","first-page":"319","article-title":"Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma","volume":"19","author":"Yip","year":"2008","journal-title":"Oncology Rep"},{"key":"10.1016\/j.ejca.2010.04.004_bib59","first-page":"2595","article-title":"Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival","volume":"8","author":"Hui","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib60","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1097\/MLG.0b013e3181805134","article-title":"The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma","volume":"118","author":"Pan","year":"2008","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejca.2010.04.004_bib61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2003.10.038","article-title":"Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy","volume":"59","author":"Chua","year":"2004","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.yexcr.2004.09.030","article-title":"Nuclear accumulation of epidermal growth factor receptor and acceleration of G1\/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1","volume":"303","author":"Tao","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib63","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1128\/JVI.00125-08","article-title":"Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3","volume":"82","author":"Kung","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2010.04.004_bib64","doi-asserted-by":"crossref","first-page":"12954","DOI":"10.1128\/JVI.01601-07","article-title":"Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer\/Bcl-3 complexes","volume":"81","author":"Thornburg","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2010.04.004_bib65","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/ijc.23415","article-title":"Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression","volume":"122","author":"Ma","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib66","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hed.20792","article-title":"Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma","volume":"30","author":"Chua","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2010.04.004_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00280-007-0575-8","article-title":"A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy","volume":"62","author":"Ma","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2010.04.004_bib68","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.2005.02.147","article-title":"Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib69","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1359-6349(09)71618-0","article-title":"A phase II trial of erlotinib after gemcitabine plus platinum-based chemotherapy in patients (pts) with recurrent and\/or metastatic nasopharyngeal carcinoma (NPC)","volume":"7","author":"You","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ejca.2010.04.004_bib70","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1200\/jco.2008.26.15_suppl.6055","article-title":"A phase II study of concurrent cetuximab-cisplatin, intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)","volume":"26","author":"Ma","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib71","unstructured":"Study of cetuximab in nasopharyngeal carcinoma (NPC) with chemoradiotherapy (ENCORE). <http:\/\/www.clinicaltrials.gov> [accessed 14.03.10]."},{"key":"10.1016\/j.ejca.2010.04.004_bib72","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib74","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib75","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1200\/JCO.2007.14.8924","article-title":"Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21","volume":"26","author":"Zhu","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib76","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib77","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib78","doi-asserted-by":"crossref","unstructured":"Merlano MC, Numico G, Russi EG, et al. Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): a phase II study. J Clin Oncol 2007;25(18s):6043 [abstract].","DOI":"10.1200\/jco.2007.25.18_suppl.6043"},{"key":"10.1016\/j.ejca.2010.04.004_bib79","doi-asserted-by":"crossref","unstructured":"Langer CJ, Lee JW, Patel UA, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2008;26(May 20 Suppl):6006 [abstract].","DOI":"10.1200\/jco.2008.26.15_suppl.6006"},{"key":"10.1016\/j.ejca.2010.04.004_bib80","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1099\/vir.0.2008\/003392-0","article-title":"Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro","volume":"89","author":"O\u2019Neil","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.ejca.2010.04.004_bib81","doi-asserted-by":"crossref","first-page":"8826","DOI":"10.1158\/0008-5472.CAN-05-0591","article-title":"Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF alpha concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9","volume":"65","author":"Stevenson","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib82","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2006.10.2871","article-title":"Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma","volume":"25","author":"Elser","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib83","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00005537-199905000-00024","article-title":"Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma","volume":"109","author":"Wakisaka","year":"1999","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejca.2010.04.004_bib84","unstructured":"Bevacizumab, cisplatin, radiation therapy, and fluorouracil in treating patients with stage IIB, stage III, stage IVA, or stage IVB nasopharyngeal cancer. <http:\/\/www.clinicaltrials.gov> [accessed 10.02.10]."},{"key":"10.1016\/j.ejca.2010.04.004_bib85","doi-asserted-by":"crossref","unstructured":"Wolmark N, Yothers G, O\u2019Connell M, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2009;27(18s):LBA4 [abstract].","DOI":"10.1200\/jco.2009.27.18s.lba4"},{"key":"10.1016\/j.ejca.2010.04.004_bib86","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.004_bib87","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-08-1306","article-title":"Novel therapeutic inhibitors of the c-Met signaling pathway in cancer","volume":"15","author":"Eder","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0002-9440(10)61669-0","article-title":"Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma","volume":"159","author":"Horikawa","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2010.04.004_bib89","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1074\/jbc.275.12.8806","article-title":"Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells","volume":"275","author":"Jo","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2010.04.004_bib90","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1158\/0008-5472.CAN-04-0538","article-title":"Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma","volume":"64","author":"Morrison","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib91","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.04.004_bib92","doi-asserted-by":"crossref","unstructured":"Ma BB, Lui VW, Hui EP, et al. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs; 2009 [Epub ahead of print].","DOI":"10.1007\/s10637-009-9269-x"},{"key":"10.1016\/j.ejca.2010.04.004_bib93","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4161\/cbt.8.4.7433","article-title":"Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma","volume":"8","author":"Yang","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2010.04.004_bib94","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1349-7006.2008.00836.x","article-title":"Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions","volume":"99","author":"Ma","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2010.04.004_bib95","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clon.2008.07.001","article-title":"Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide","volume":"20","author":"Xueguan","year":"2008","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib96","doi-asserted-by":"crossref","first-page":"9870","DOI":"10.1158\/0008-5472.CAN-06-1679","article-title":"EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells","volume":"66","author":"Kondo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib97","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1128\/MCB.24.12.5223-5234.2004","article-title":"Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha","volume":"24","author":"Wakisaka","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejca.2010.04.004_bib98","doi-asserted-by":"crossref","unstructured":"Diaz-Padilla I, Siu LL, Duran I. Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest New Drugs; 2009 [Epub ahead of print].","DOI":"10.1007\/s10637-009-9236-6"},{"key":"10.1016\/j.ejca.2010.04.004_bib99","first-page":"2039","article-title":"P16 gene alterations in nasopharyngeal carcinoma","volume":"55","author":"Lo","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.virusres.2005.04.019","article-title":"Latent membrane protein 1 encoded by Epstein-Barr virus modulates directly and synchronously cyclin D1 and p16 by newly forming a c-Jun\/Jun B heterodimer in nasopharyngeal carcinoma cell line","volume":"113","author":"Song","year":"2005","journal-title":"Virus Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib101","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ijc.20065","article-title":"Potential efficacy of p16 gene therapy for EBV-positive nasopharyngeal carcinoma","volume":"110","author":"Li","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib102","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-08-2790","article-title":"Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma","volume":"15","author":"Hui","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib103","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-08-1748","article-title":"Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer","volume":"15","author":"Hsieh","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"18s","key":"10.1016\/j.ejca.2010.04.004_bib104","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1200\/jco.2009.27.15_suppl.6026","article-title":"A phase II randomized study of oral selicilib in patients with previously treated nasopharyngeal carcinoma","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ijc.20079","article-title":"RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma","volume":"109","author":"Chow","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib106","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/(SICI)1097-0215(19990812)82:4<498::AID-IJC5>3.0.CO;2-S","article-title":"Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation","volume":"82","author":"Hui","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib107","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/sj.bjc.6690818","article-title":"Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma","volume":"81","author":"Wang","year":"1999","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib108","first-page":"131","article-title":"Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma","volume":"8","author":"Kwong","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib109","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/CBM-2005-1602","article-title":"Down regulation of adhesion protein E-cadherin in Epstein-Barr virus infected nasopharyngeal carcinomas","volume":"1","author":"Krishna","year":"2005","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.ejca.2010.04.004_bib110","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1593\/neo.05217","article-title":"Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues","volume":"7","author":"Zhou","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejca.2010.04.004_bib111","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/scbi.1999.0137","article-title":"DNA methylation and the Epstein-Barr virus","volume":"9","author":"Ambinder","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejca.2010.04.004_bib112","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2004.04.185","article-title":"Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors","volume":"22","author":"Chan","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib113","first-page":"1427","article-title":"Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth","volume":"30","author":"Hattori","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib114","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib115","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-03-0297","article-title":"The clinical application of targeting cancer through histone acetylation and hypomethylation","volume":"10","author":"Gilbert","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib116","unstructured":"Vorinostat and azacitidine in treating patients with locally recurrent or metastatic nasopharyngeal cancer or nasal natural killer T-cell lymphoma. <http:\/\/www.clinicaltrials.gov> [accessed 19.02.10]."},{"key":"10.1016\/j.ejca.2010.04.004_bib117","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1471-2407-6-283","article-title":"Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1, the immunomodulatory protein galectin 9","volume":"6","author":"Keryer-Bibens","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib118","first-page":"185","article-title":"Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma","volume":"4","author":"Zheng","year":"2007","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ejca.2010.04.004_bib119","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/path.1569","article-title":"Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma","volume":"203","author":"Heussinger","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.ejca.2010.04.004_bib120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semcancer.2008.10.002","article-title":"Immune escape by Epstein-Barr virus associated malignancies","volume":"18","author":"Munz","year":"2008","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejca.2010.04.004_bib121","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00262-007-0427-8","article-title":"CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients","volume":"57","author":"Lin","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2010.04.004_bib122","doi-asserted-by":"crossref","first-page":"e1122","DOI":"10.1371\/journal.pone.0001122","article-title":"Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy","volume":"2","author":"Li","year":"2007","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2010.04.004_bib123","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.1430","article-title":"Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma","volume":"94","author":"Chua","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib124","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","article-title":"Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.04.004_bib125","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib126","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1200\/jco.2009.27.15_suppl.6025","article-title":"Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC)","volume":"27","author":"Wirth","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib127","unstructured":"Study of LMP1- and LMP2-specific cytotoxic T-lymphocytes (CTL) given with CD45 monoclonal antibody (MAb) in patients with Epstein Barr virus (EBV)-positive nasopharyngeal carcinoma (DELLA). <http:\/\/www.clinicaltrials.gov> [accessed 10.02.10]."},{"key":"10.1016\/j.ejca.2010.04.004_bib128","first-page":"6952","article-title":"Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.004_bib129","unstructured":"Vaccine therapy or observation in treating patients with nasopharyngeal cancer at high risk for recurrence. <http:\/\/www.clinicaltrials.gov> [accessed 10.02.10]."},{"key":"10.1016\/j.ejca.2010.04.004_bib130","unstructured":"Peptide vaccine to prevent recurrence of nasopharyngeal cancer. <http:\/\/www.clinicaltrials.gov> [accessed 10.02.10]."},{"key":"10.1016\/j.ejca.2010.04.004_bib131","unstructured":"Vaccine therapy and celecoxib in treating patients with metastatic nasopharyngeal cancer. <http:\/\/www.clinicaltrials.gov> [accessed 10.02.10]."},{"key":"10.1016\/j.ejca.2010.04.004_bib132","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12032-007-0052-6","article-title":"Mature results of neoadjuvant chemotherapy followed by radiotherapy in nasopharyngeal cancer: is it really old fashioned?","volume":"25","author":"Kamer","year":"2008","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib133","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hed.20189","article-title":"Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns","volume":"27","author":"Leung","year":"2005","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2010.04.004_bib134","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.5732\/cjc.009.10427","article-title":"Concurrent control study of different radiotherapy for primary nasopharyngeal carcinoma: intensity-modulated radiotherapy versus conventional radiotherapy","volume":"28","author":"Zhang","year":"2009","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.ejca.2010.04.004_bib135","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.ijrobp.2008.05.023","article-title":"Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors","volume":"73","author":"Lee","year":"2009","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib136","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0360-3016(97)00580-4","article-title":"Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma","volume":"40","author":"Lee","year":"1998","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib137","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1200\/JCO.2008.19.1866","article-title":"Bevacizumab reverses cerebral radiation necrosis","volume":"26","author":"Wong","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib138","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2006.10.010","article-title":"Effect of bevacizumab on radiation necrosis of the brain","volume":"67","author":"Gonzalez","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib139","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdf241","article-title":"Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients","volume":"13","author":"Schagen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2004.10.004","article-title":"The effects of adjuvant chemotherapy on cognition in women with breast cancer \u2013 preliminary results of an observational longitudinal study","volume":"14","author":"Shilling","year":"2005","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2010.04.004_bib141","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","article-title":"Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up","volume":"8","author":"Douw","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejca.2010.04.004_bib142","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11060-009-9923-3","article-title":"Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03","volume":"95","author":"Corn","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2010.04.004_bib143","doi-asserted-by":"crossref","unstructured":"Gan H, Bernstein L, Brown J, et al. Neurocognitive outcomes of head and neck chemoradiotherapy: a pilot study. J Clin Oncol 2009;27(18s):6068 [abstract].","DOI":"10.1200\/jco.2009.27.15_suppl.6068"},{"key":"10.1016\/j.ejca.2010.04.004_bib144","unstructured":"Hsiao KY, Yeh SA, Chang CC, et al. Cognitive function before and after intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: a prospective study. Int J Radiat Oncol; 2009 [Epub ahead of print]."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T07:05:34Z","timestamp":1635318334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910003072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":144,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0959804910003072"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.04.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}